Worth reading
29Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Who is moving to which position
Resolved 26 June 2026Incoming appointee
1 itemScheduled Appointment Date26 June 2026
Sugii Kei (杉井 圭)
Previous positionDirector and COO (also serving as President of the Prescription Medicines Company)
New positionRepresentative Director and COO (also serving as President of the Prescription Medicines Company)
生年月日 Born 16 December 1969入社年 2009所有株式数 10,900 shares (reference date: Not disclosed)
Whether the incumbent will remain in office (whether they will retain their position)
Sugii Kei (杉井 圭) will remain a Director
Reason for change
To further strengthen the management structure and establish a framework for faster decision-making
| Item | Details |
|---|---|
| Resolution date | 26 June 2026 |
| Scheduled Appointment Date | 26 June 2026 |
| Name of appointee | Sugii Kei (杉井 圭) |
| Appointee's new position | Representative Director and COO (also serving as President of the Prescription Medicines Company) |
| Appointee's previous position | Director and COO (also serving as President of the Prescription Medicines Company) |
| Appointee's date of birth | Born 16 December 1969 |
| Year the appointee joined the Company | 2009 |
| Number of shares held by the appointee | 10,900 shares (reference date: Not disclosed) |
| Whether the incumbent will remain in office | Sugii Kei (杉井 圭) will remain a Director |
| Reason for change | To further strengthen the management structure and establish a framework for faster decision-making |
Items this document does not state (11)
Date of departureName of departing officerFormer position of departing officerNew position of departing officerReason for departureReasons for appointmentNumber of directors after the changeFiling as an independent officerDetails of organizational changesChange in Corporate Governance StructureSubject to Approval by the General Meeting of Shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To further strengthen the management structure and establish a framework for faster decision-making
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.